SUMMARY
Individual uptake of tobacco smoke constituents by smoking is highly variable in cigarette smokers and cannot be predicted by smoking behaviour variables and machinederived smoke yields. It is well established that uptake of smoke constituents is best described by a series of biomarkers of exposure (BOEs) such as metabolites of nicotine, tobacco-specific nitrosamines (TSNAs), polycyclic aromatic hydrocarbons (PAHs), aromatic amines, benzene, 1,3-butadiene, acrolein, hydrogen cyanide, 2,5-dimethylfuran and other smoke constituents. The purpose of this review is to investigate the relationship between BOE levels and machine-derived smoking yields on the basis of published data. The influence of other smoking behaviour variables, in particular the number of cigarettes smoked per day (CPD) and smoking topography (puffing and inhalation patterns) is also considered, provided suitable data are available. Twenty eight (28) published studies, which report data on machine-derived smoke yields and biomarker concentrations in body fluids of smokers of these products were identified. In total, 33 different BOEs were applied in these studies. Important properties of the BOEs used in the further evaluation were described and discussed.
In almost all studies selected, data for CPD were reported.
In only a few studies, puffing and inhalation profiles have been determined so that no systematic evaluation of the association between smoking topography and BOE levels was possible. In the studies evaluated, no statistically significant association between daily cigarette consumption (CPD) and smoke yields was observed. This clearly indicates that low machine-derived yields were not compensated by increasing the daily cigarette consumption. As expected, positive and statistically significant relationships were found between CPD and BOE levels for most of the biomarkers investigated. Bi-and multivariate linear regressions were calculated for the relationships between BOE levels (dependent variable) and machine-derived yields as well as CPD (independent variables). Whenever possible, results from various studies were combined (this was only possible, when identical biomarkers and yield types were available). Aggregation of the results from all studies independent of BOE and yield type used is feasible on the basis of relative BOE and yield levels. The multivariate linear regression models obtained reveal that both CPD and machine-derived yields are significant predictors of the measured BOE levels. The models predict that, on average, a 50% reduction in CPD or yield are accompanied by a 33 or 15% reduction, respectively, in smoke uptake, as measured by various BOEs. Taken together, the evaluated data from the literature show that lower machine-derived yields lead to a reduced uptake of smoke constituents. The reduction is statistically significant, but substantially lower than the decrease in machinederived yields. (7) (8) (9) . CPD can be easily assessed by means of questionnaires, however, the self-reported information might be of limited reliability (10, 11) . Puffing and inhalation intensities are also important for varying the smoking dose (12) (13) (14) (15) (16) . These parameters are more difficult to assess compared to the CPD information. In addition, measurement of the smoking topography may interfere and modify the natural smoking process (17 yield' or 'yield in use') can be determined by the part filter methodology which has been established and applied in recent years (18) (19) (20) . This methodology determines only the mouth level exposure but not what is actually absorbed into the body, although both smoking dose variables are strongly correlated (21, 22) . Another limitation is the fact that each cigarette brand requires its individual calibration for determining the yield in use level. This restriction is circumvented by measuring biomarkers of exposure (BOEs) in body fluids of smokers (for review, see (23) (24) (25) ). BOEs for smoke exposure are either unchanged smoke constituents, their metabolites or reaction products with macromolecules (adducts), which reflect the internal exposure dose (26) . General limitations of human biomonitoring include the fact that the route of uptake as well as the source of exposure is not known. The latter issue can be circumvented by measuring BOEs to tobacco-specific smoke constituents such as nicotine and tobacco-specific nitrosamines (TSNAs). However, if BOEs for smoke toxicants such as carbon monoxide (CO), polycyclic aromatic hydrocarbon (PAH), aldehydes, hydrogen cyanide (HCN), benzene, etc., which may originate from many sources other than tobacco smoke, are of interest, appropriate study designs are required in order to obtain useful information. Despite of these restrictions, the measurement of suitable BOEs is nowadays the best approach for assessing the actual smoking dose. Data on BOEs along with information on smoking machine-derived yields and CPD, therefore, provide the basis for investigating the central question of this review:
• What is the relationship between the actual smoking dose and the machine-derived smoke yields of cigarettes? For this purpose, suitable published studies from the peer reviewed literature were selected. In order to be included in the evaluation, the studies must contain data on machinederived smoke yields (at least two yield levels or ranges of yields (bands)) and the corresponding BOE concentrations in smokers of these products. CPD data for each yield group should be also available (which is the case for all but one of the selected studies). Information on smoking topography was also extracted from the selected studies, but could not be evaluated systematically, since only a few studies provided this information in addition to BOE and yield data. As a general approach for statistical evaluation, linear regressions between BOE and yield levels or CPD as well as between CPD and yield were calculated (bivariate evaluation). In multivariate linear regression analyses, models for BOE levels (dependent variable) considering yield and CPD as independent variables were also calculated. Whenever possible, data from different studies were aggregated for evaluation. 
METHODS

Selection of suitable publications
Biomarkers for nicotine
Nicotine is usually regarded as tobacco and tobacco smokespecific. Possible interference from other nicotine containing products, such as patches, chewing gums, inhalers and electronic cigarettes has to be considered and, if applicable, eliminated. At low nicotine exposure levels, such as exposure of non-smokers to environmental tobacco smoke (ETS), other sources of nicotine, in particular certain food items (31-33) may interfere and need to be considered as well. Nicotine in body fluids has a very short half-life (initial half-life: 8 min; terminal half-life: 2 h (34)) and, therefore, reflects the acute uptake of nicotine. Thus, application of nicotine as a biomarker in smoking behaviour studies would require strict control of time to last smoking prior to sample collection. Urinary nicotine levels are dependent on the pH and the urinary flow and are, therefore, relatively variable (34). Nicotine in saliva is a less suitable biomarker, since it originates not only from systemically absorbed nicotine, but also from the exogenous alkaloid in the mouth of the smoker. Additionally, nicotine is actively secreted by the submandibular and parotid salivary glands, which contributes to the high variability of nicotine concentrations in mixed saliva, which is usually collected (35). Therefore, cotinine, rather than nicotine is preferably used as a BOE to nicotine and tobacco or tobacco smoke. In particular, cotinine in blood (plasma or serum) and saliva are highly suitable for this purpose (36). Since cotinine in blood and saliva are strongly correlated, these two biological matrices can be used inter-changeably (37-39). Due to its non-invasive collection, saliva might have advantages for some types of studies. trans-3'-Hydroxycotinine (OH-Cot) is a further major metabolite of nicotine formed from cotinine. As a BOE to nicotine it has no advantages over cotinine when taken by itself. However, OH-Cot in body fluids is of interest for phenotyping rapid and slow metabolizers of nicotine by the determination of the OH-Cot/cotinine ratio (40-42). Furthermore, OH-Cot and its O-and N-glucuronides represent the major nicotine metabolites in urine. Together with the free and conjugated nicotine and cotinine, these urinary nicotine metabolites constitute about 80% of the absorbed nicotine dose (also termed 'nicotine equivalents' or 'Nic+5') (34, 43, 44). Nic+5 has been frequently used as a biomarker for estimating the nicotine dose excreted in the 24-h-urine (21, (45) (46) (47) (48) (49) (50) (51) . In extension of the Nic+5 method, a Nic+9 method (assessing additionally nornicotine, norcotinine, nicotine-N-oxide and cotinine-Noxide) and a Nic+10 method (considering in addition the nicotine metabolite 4-hydroxy-4-(3-pyridyl)-butanoic acid (HyPyBut)) are also available, reflecting about 90 and 98%, respectively, of the total dose of absorbed nicotine (43, 44, 52-55). As yet, however, no data have been published applying these extended methods in studies of interest for this review. Biomarkers for nicotine, especially cotinine, have been also applied for assessing ETS exposure of non-smokers. Clear dose-response-relationships were observed (36, 56, 57) . This has to be taken into account when the ratio of biomarker levels between cigarette smokers (CS) and nonsmokers (NS) is investigated. This ratio (last column of the table in Supplementary Data 1) is an indicator of the specificity of a biomarker for tobacco smoke exposure. For BOEs to nicotine, the ratio CS/NS is usually ~ 100. If the non-smokers are actual passive smokers (PS), the CS/PS ratio can be significantly lower (36). A cutoff for differentiating smokers and non-smokers of about 15 ng/mL has been proposed (for review, see (44)).
Biomarkers for hydrogen cyanide (HCN) and carbon monoxide (CO)
The first reported biomarker of the (internal) smoking dose was thiocyanate (SCN), a detoxification product of cyanide, determined in urine, saliva and blood. Claude Bernard (1813-1878) discovered that smokers excreted higher amounts of SCN in their urine than non-smokers (58, 59 (64) . This leads to a substantial overlap of the SCN concentration ranges of smokers and non-smokers. The CS/NS ratio is about 2, which plainly emphasizes the described background problem. It should be also mentioned that SCN levels in saliva are about 20-fold higher than in blood or urine, indicating active transport of SCN from blood into saliva (39). Carboxyhemoglobin (COHb) has been used as BOE for the smoking-related CO uptake for almost one century (for review see (64)). COHb has a half-life of 2-4 h, depending on the physical activity, and, therefore, indicates the acute exposure to CO. There are a couple of other sources for COHb such as CO in ambient air (originating mainly from traffic exhausts) and endogenous formation by haem degradation (65) . This is reflected in CS/NS ratios for COHb of 4-6 (Supplementary Data 1). A particular property of COHb is that it reflects smoke inhalation, since CO can be taken up only through the alveoli (64) . CO in exhaled breath is in equilibrium with COHb in blood. In numerous studies (66) (67) (68) (69) (70) , strong correlations between COHb and CO in exhaled breath (COex) were observed. The non-invasively assessable COex can therefore be used as a fully equivalent surrogate marker for COHb as a biomarker for CO uptake.
Biomarkers for tobacco-specific nitrosamines (TSNAs)
The TSNAs include 4-
and N-nitrosoanatabine (NAT). Most human biomonitoring data on TSNA exposure are available for total urinary 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL), which is the molar sum of free and conjugated NNAL, representing the major metabolites of NNK in urine. NNAL shows a biphasic elimination from the body with half-lives of about 28 h and 18 d for the initial and terminal phases, respectively (71, 72) . This has to be taken into account in the study design, when using NNAL as a BOE. Total urinary NNAL is also elevated in ETS exposed non-smokers (2) . Published CS/NS ratios for NNAL range from < 50 to > 500, for which variations in the numerator (NNAL levels in smokers) and the denomi-nator (NNAL levels in non-smokers) are responsible (73, 74) . Analytical methods for the determination of biomarkers for all four TSNAs (NNAL, NNN, NAB and NAT in urine) have been published (75, 76) . Sufficient data for evaluating the association between biomarker levels and nominal yields in mainstream smoke of cigarettes are only available for NNAL. It should be also noted that, for unknown reasons, the HPB (4-hydroxy-1-(3-pyridyl)-1-butanone)-releasing hemoglobin adducts, which are formed from enzymatically activated NNK and NNN, show no clear dose-response-relationship to tobacco smoke exposure and cannot be used as a BOE (77-80).
Biomarkers for polycyclic aromatic hydrocarbons (PAHs)
PAHs are formed during all incomplete combustion processes of organic materials and comprise more than 500 compounds (81) . For characterizing the exposure to this class of compounds, usually only a few representative metabolites are selected. The most frequently used BOE for uptake of PAHs is total (free + conjugated) urinary 1-hydroxypyrene (1-OH-Pyr), originating from pyrene exposure (82 Other sources for exposure to PAHs are smoked, grilled and fried food, leafy vegetables, combustion gases and some topical coal "tar" medications. As a result, there are significant background levels in non-smokers leading to CS/NS ratios of about 2-6 (Supplementary Data 1).
Mercapturic acids (MAs) and trans,trans-muconic acid (ttMA)
MAs in urine are detoxification products originating from various toxicants present in smoke and other environmental media, which are either electrophiles on their own (e.g., acrolein or crotonaldehyde) or metabolically converted to electrophiles (e.g., benzene or 1,3-butadiene). The electrophiles react with the nucleophilic sulfur in glutathione (GSH) and are subsequently metabolized to MAs, which are excreted into urine. Data for evaluation of the association between biomarker levels and mainstream smoke yields are available for S-phenyl-mercapturic acid (SPMA, metabolite of benzene), 3-hydroxypropyl-mercapturic acid (HPMA, metabolite of acrolein), monohydroxybutenyl-and dihydroxybutyl-mercapturic acid (MHBMA and DHBMA, respectively, metabolites of 1,3-butadiene). These MAs have elimination half-lives of about 9-12 h (93) and are thus short-term BOEs. Non-smokers have measurable background levels of these MAs, resulting in CS/NS ratios of about 4-12. Particularly high background concentrations are found for DHBMA (CS/NS ratio < 2), therefore this metabolite is of limited value as a BOE for the smokingrelated uptake of 1,3-butadiene (94, 95) . ttMA is another urinary metabolite of benzene, which is frequently used as a BOE. Despite the fact that a substantial part of the benzene exposure dose is excreted as ttMA into urine (2-25% for ttMA compared to 0.1-0.5% for SPMA, (96)), SPMA is a more specific and suitable BOE for the smoking-related benzene uptake than ttMA, with average CS/NS ratios of 6.5 and 1.5, respectively (Supplementary Data 1). The reason is that ttMA is also formed as a metabolite from the food preservative sorbic acid, which significantly interferes with ttMA formed from benzene exposure, especially at low exposure levels (96).
Bulk biomarkers
Bulk biomarkers such as urinary thioethers and mutagenic activity indicate the exposure to a class of compounds with similar chemical/toxicological properties such as electrophilic (measured as the sum parameter 'thioethers') and mutagenic chemicals (measured as the sum parameter 'mutagenic activity') (97) (98) (99) . Thioethers comprise the bulk of all mercapturic acids (MAs) assessable by this methodology (and probably many other sulfur-containing compounds). In terms of elimination half-life, in general the same applies as for urinary MAs. Specificity for tobacco smoke is probably lower than for the MAs mentioned in the previous section, since significant dietary uptake of interfering compounds has to be assumed (100, 101). Consequently, the CS/NS ratio for urinary thioether levels is in the range of 1.5 and thus of borderline suitability as a BOE for tobacco smoking. An advantage of this bulk biomarker is undoubtedly the fact that the toxicants (electrophiles) leading to increased thioether levels must not be identified prior to application of this methodology. Increased urinary mutagenicity in smokers compared to non-smokers was first reported by YAMASAKI and AMES (102) . There is a strong influence of diet on the mutagenic activity in urine, therefore, the CS/NS ratio may vary considerably (CS/NS: 10-30), depending on the level of dietary control (2, 27, 87) . The smoking-related urinary mutagenicity reaches non-smoker levels within 6-13 h after smoking cessation (103, 104) . Detection of the mutagenic activity is usually performed with the Salmonella typhimurium tester strains TA98 or YG1024 in the presence of a microsomal activation system. The tobacco smokederived mutagens are primarily particle phase constituents (105) . Despite some earlier assumptions that heterocyclic aromatic amines (HAA) together with aromatic amines might be mainly responsible for the mutagenic activity of smokers' urine (106-108), recent findings indicate that HAA explain probably only less than 10% of the mutagenic activity of smoke particles (109) . Again, an advantage of this bulk biomarker is the fact that the toxicants (mutagens) leading to increased mutagenic activities must not be identified in order to apply this method.
Protein adducts
Protein adducts can be regarded as a special case of BOEs. They are referred to as 'biomarkers of effective dose', since their formation usually requires metabolic activation of the parent compound (110) (111) (112) . Biomarkers of effective dose, therefore, not only reflect the exposure dose, but also the capacity of the organism to enzymatically activate the compounds of interest to generate the toxic intermediates (e.g., the ultimate carcinogens). Protein adducts for human biomonitoring purposes (most frequently hemoglobin or albumin adducts) are usually of no physiological or toxicological relevance, but rather are used as plain dosimeters, which indicate the accumulated dose over the lifetime of the protein (120 d for hemoglobin, half-life of human serum albumin: 20 d). Available data of protein adducts for studying the association between adduct levels and mainstream smoke yields of cigarettes include the following biomarkers: 2-cyanoethylvaline hemoglobin (CEVal, BOE to acrylonitrile), 2-hydroxyethylvaline hemoglobin (OHEtVal, BOE to ethylene oxide and ethylene), methylvaline hemoglobin (MeVal, BOE to methylating agents), carbamoylethylvaline hemoglobin (AAVal, BOE to acrylamide) and 4-aminobiphenyl hemoglobin (4-ABP-Hb, BOE to 4-aminobiphenyl). These adducts reflect the chronic exposure to the smoke toxicants indicated over the last 3-4 months. The adduct with the highest specificity for tobacco smoke is CEVal (CS/NS ratio: 17 (47). The least specific BOE is MeVal (CS/NS ratio: 1.3 (47), primarily owing to substantial endogenous methylation processes. Protein adducts (in particular hemoglobin adducts) are not suitable for short-term studies lasting for several days up to a few weeks. They are, however, ideally suited for longterm field studies lasting for several months up to years (e.g., evaluation of new smoking products in post-market studies (5, 113)).
ASSOCIATION BETWEEN BOE LEVELS AND YIELDS AND/OR CPD
In the Supplementary Data 2, data extracted from the 28 selected studies (9, 47, 49, 50, 52, 53, 83, 114-134) for the described statistical evaluations are compiled. Each study consists of one or more data sets comprising values for cigarette mainstream smoke yields, BOE levels and CPD. One selected study (116) did not report CPD data. Some studies do not contain separate data for yields, BOEs and CPD, but rather report the results of the correlations and regressions of interest (9, 115, 118, 122) . These studies were not included in the evaluations performed for this review, but reported results were listed for information only. Furthermore, in the last column of the table in the Supplementary Data 2 it is indicated, in which statistical evaluations the study data have been used. In the following two sections (4.1 and 4.2), results of bivariate regressions and multivariate regression models, respectively, are presented. The bivariate evaluation comprises the associations between BOEs and yields, BOE and CPD, as well as CPD and yield. The multivariate evaluation includes linear regression models for BOE (dependent variable) and yield as well as CPD (independent variables). In other words, these models provide quantitative data on how well the BOE levels are predicted by yields and CPDs or how much of the variability in the BOE levels is explained by yield and CPD. The bivariate associations and the multivariate models are based on the same subsets of selected data from the 28 studies. The characteristics of these datasets are summarized in Table 1 . Aggregation of data with absolute units of BOEs and yields (as is the case with the first 5 datasets in A general limitation of the evaluations presented in this review is the inherent variability of both smoke yield and BOE data, which are generated in different laboratories. While there are analytical standard methods and frequent ring-trials available for smoke yields of "tar", nicotine and CO, this is not the case for analysis of BOEs (although corresponding activities for BOEs are presently driven forth). This limitation has to be kept in mind when interpreting the results.
Bivariate analysis
The associations between smoking behaviour variables such as CPD, puffing and inhalation patterns and the measurable uptake of smoke constituents by BOEs are only a secondary aspect of this review. The selected studies contain information on CPD and other smoking behaviour variables (Supplementary Data 2). In only a few of the studies, results for puffing or inhalation patterns are reported (9, 124, 129, 133) . In one study (133) , a weak but statistically significant relationship between self-reported inhalation pattern and nicotine uptake was found (r = 0.20, p = 0.002). In another study (129) , no measurable influence of the extent of inhalation (assessed by questionnaire) on urinary cotinine levels was stated. MUHAMMAD-KAH and coworkers (9) found that important smoking topography parameters were total puff volume, puff count and total inter-puff interval. Together with CPD and yield, these parameters explain about 30-40% of the variability in daily exposure to nicotine and carbon monoxide. HEE et al. (124) observed that the total puff volume did not significantly change in relation to smoke yields, whereas the inhalation index significantly decreased with increasing yields. In all but one study (116) , which were included in the evaluation of the relationship between machine-derived smoke yields and biomarker levels, CPD data were reported. In numerous studies, the importance of CPD for the smoking dose as well as the implicated health risks has been emphasized (1-3). In this bivariate evaluation, the following associations were investigated:
• BOE versus CPD • BOE versus yield • CPD versus yield Table 2 shows the results of this analysis for the 8 selected datasets described in Table 1 . These results show that the BOE levels are significantly associated with CPD and with the machine-derived yields for all selected datasets except for # 3 (nicotine equivalents Nic+5 versus cigarette nicotine yields) and # 6 (1-hydroxypyrene versus "tar" yield). The latter finding is not surprising, due to the limited number of studies available and the non-specificity of this biomarker for tobacco smoke exposure. The lacking statistical significance for the association between Nic+5 in urine and either CPD or nicotine yield is somewhat unexpected. A number of reasons might have caused this result, including limited number of studies included (only three studies) and the low variability in the CPD variable in the largest of these 3 studies (49). The association between BOE levels and CPD is in some cases stronger (# 1, 2, 5), in other cases (# 4, 7, 8) similar or weaker than the association between BOE levels and yields. This is also somewhat unexpected since in most previous studies (7, 9, 118) the correlation between BOE and CPD was found to be stronger. A plausible explanation for this finding is the fact that in this analysis, average CPD values instead of individual CPDs have to be used for each yield level, thus levelling off the variability in this parameter leading to, in general, weaker correlations. The use of individual CPD data would have been preferable, however, were not available from the published data. Table 2 further indicates that there is no significant correlation between CPD and machine-derived yield levels, suggesting that the daily cigarette consumption is not increased in smokers of lower yield cigarettes. This observation has been emphasized in an earlier review (4) . Also in this evaluation, the above discussed limitation of using average CPD values has to be taken into account.
As an example, the three linear regressions for the selected data base # 1 are shown in Figures 1-3 . COULTAS et al. (118) reported significant coefficients of correlation (r) of 0.51 and 0.52 for the association between salivary cotinine and CPD and between CO in exhaled breath and CPD, respectively. BENOWITZ et al. (115) found a significant r value of 0.40 between cotinine in plasma and cigarette consumption. MUHAMMAD-KAH et al. (9) concluded from their data that the number of cigarettes smoked per day is the most important factor in the model for predicting nicotine equivalents (Nic+5) in urine and COHb levels. Note that these results are based on individual data Number of sub-datasets can be higher than number of studies, since some studies comprise more than one data set, for example when males and females were investigated separately or when several biomarkers were evaluated. Total numbers of subjects of all studies considered in a subset of data for evaluation. Subjects are multiple counted, if more than one biomarker is evaluated in a study.
for CPD and BOE levels. Further results for the association between CPD and BOE concentrations have been summarized in an earlier review (4). GORI and LYNCH (122) stated that CPD is not affected by the FTC nicotine yield of the smoked cigarettes. In a review on smoking behaviour and compensation (4), it was concluded that the number of cigarettes is not a significant factor for compensation. These findings are in agreement with the evaluation presented here, which also shows no significant relationship between CPD and smoke yield levels.
Multivariate analysis
The association between the actual uptake of smoke constituents, measured by suitable biomarkers of exposure (BOEs), and the corresponding machine-derived yields in mainstream smoke of cigarettes is in the focus of this review. Published studies which allow the investigation of this relationship have been especially selected for this purpose (the studies selected are compiled in the Supplementary Data No 2). The BOEs applied in these studies have been characterized and discussed in Chapters 3 and 4.1. The influence of smoking behaviour parameters such as puffing pattern, extent of inhalation and daily cigarette consumption (CPD), as far as these variables were considered in the selected studies, were evaluated in the previous section. CPD was the only smoking behaviour variable, which was included in almost all studies. As found in previous reviews (4, 29), nicotine and "tar" yields have no significant impact on average daily cigarette consumption.
On the other hand, BOE levels significantly increase with CPD (73, (135) (136) (137) . Average daily cigarette consumption (CPD) was found to be the strongest predictor for smokingrelated BOE concentrations in body fluids (9, 138) . It is, therefore, important to take into account the variable CPD when investigating the association between BOE and yield levels in cigarette smokers. The consideration of other influencing factors such as gender, age, cigarette blend type, puffing and inhalation profile would be of general interest. However, these influencing factors could not be systematically studied in this review, due to lack of suitable information in the selected studies.
In this section, the results of multivariate analyses of the 8 datasets as described in Table 1 are presented and discussed.
Stepwise linear regression models are calculated using the following variables:
• BOE, either with absolute units (datasets # 1-6) or relative units (%, datasets # 7 and 8) as dependent variable • CPD, either with absolute units (cigarettes/d, datasets # 1-6) or in relative units (%, datasets # 7 and 8) as independent variable • Smoking machine-derived yields according to ISO or FTC (mg/cigarette, datasets # 1-6) or in relative units (%, datasets # 7 and 8) as independent variable. In Table 3 , the characteristics of the various models are summarized. The models generated explain between 95% (dataset # 5, COex/CO yield) and 15% (dataset # 6, 1-OHpyrene/"tar", not significant) of the variability in the BOE levels. As is obvious from Table 3 , the highest R 2 values (indicating the percentage of BOE variability explained) were obtained when BOE and yield correspond, i.e., are related to the same chemical in tobacco smoke, which is the case for the models based on the datasets # 1-5. The models based on datasets # 6-8 partially use 'surrogate' yields in case that the corresponding yields are not available from the published data. Model 8, which uses all available datasets, shows a much lower R 2 as compared to Model 7, which uses 'corresponding' or closely related BOE/yield pairs (for further discussion of this issue, see the last but one paragraph of introduction to Chapter 4). Depending on the selected dataset, the independent variables CPD and yield explain various percentages of the variability in the BOE levels. CPDs explain between 3.6 and 89.2% of the variability in BOE levels, whereas the corresponding range for yields is 6.2-42.8%. As discussed in Section 4.1, CPD usually is a significantly better predictor for BOE levels than machine-derived yields (7, 9, 118) . We assume that in this particular evaluation, the individual variations in CPD Table 4 . The predicted effects on the BOE levels when reducing either yield or CPD by 50% and keeping the respective other variable constant were calculated for all models, except for Model 6, which shows no significant contribution of any of the two independent variables. Additionally, this calculation takes into account 95% confidence intervals (CIs) of the constants and coefficients of the models. The observed CIs were relatively large and show wide overlaps between the various assumed smoking behaviours. Despite of that, the modelderived predictions show some consistent results. The models predict that reducing the daily cigarette consumption (CPD) by 50% results in an average reduction in BOE levels of 32.6% (range: 16.3-63.6%) when considering the evaluable 7 models (Table 4 ). The corresponding BOE reductions for a 50% reduction in machine-derived yields amount to 15.0 (4.2-18.9)%. This finding is in line with reports of MUHAMMAD-KAH et al. (9) , HAMMOND et al. (7) , COULTAS et al. (118) who also found that CPD is a significantly better predictor for biomarker-derived smoke uptake Table 1 ).
data as compared to machine-derived smoke yields. In a few studies (9, 115, 118, 121, 122) , results for the relationship between BOE and yield levels are presented (summarized in Supplementary Data 2) . The reported coefficients of correlation are in the range of !0.15 to 0.23 (115, 118, 121, 122) . This would correspond to an explained variability in BOE level by yield of up to 5%, which is significantly lower than the percentage explained by yield found in this evaluation. MUHAMMAD-KAH et al. (9) found that the machine measured "tar" yield was a significant factor in their model for predicting the BOEs Nic+5 and COHb, however with a relatively small contribution to the explained variability in the biomarker levels. This is in agreement with conclusions from other studies (8, 47, 49, 139) and supports the general concept of partial compensation outlined in a previous review (4). However, the extent of this (partial) compensation is still controversial and ranges from 100% (complete compensation, no association between BOE levels and machine-derived smoke yields) as suggested by some authors (29) and 70% (slope of ~ 0.3 between relative BOE and yield levels) as found in the data evaluation of this review.
SUMMARY AND CONCLUSIONS
• Twenty eight (28) published studies, which reported data on machine-derived smoke yields of cigarettes and corresponding biomarker concentrations in body fluids of smokers of these products were identified. In total, 33 different BOEs were applied in these studies.
• Important properties of the BOEs applied, such as precursors in smoke, sources other than tobacco smoke, background levels in non-smokers, half-life and smoker/non-smoker level ratios were described and discussed. Table 1 ). • In almost all studies, data for CPD were provided. In only a few studies, puffing or inhalation profiles have been determined so that no systematic evaluation of the association between puffing and inhalation variables and BOE levels was possible.
• Stepwise linear regression models were calculated with BOE as dependent variable and CPD as well as smoking machine-derived yields as independent variables. Depending on the dataset evaluated, both CPD and yield were found as significant predictors for the measurable BOE levels. In previous studies, most frequently CPD was reported to be a significantly better predictor than yield. A possible reason for this discrepancy is that fact that in this evaluation, average CPD values had to be used resulting in loss of variability in this parameter.
• The models predict that reducing the daily cigarette consumption (CPD) by 50% would result in an average reduction in BOE levels of 33%, whereas a 50% reduction in machine-derived yields would result in a mean reduction of 15% reduction in smoke uptake. 
Dataset (Model) #: 2, 7, 8  Tables:  1, 2, 3, 4  Figures: - The number of cigarettes smoked per day (CPD) is the most important factor in the models for daily exposure to nicotine.
Other important smoking-related factors were number of years smoked, smoking behaviour questions from the FTND, topography parameters (i.e., total puff duration and puff count) and "tar" yield categories. When daily exposure to nicotine is adjusted by daily cigarette butts returned (Nic+5 per cig), the most important factors contributing to exposure are the topography parameters (total puff volume, puff count and total inter-puff interval). "… In conclusion, the models investigated in the study, explain about 30-40% of variability in daily exposure to nicotine and carbon monoxide. …" 
